1. Home
  2. SYPR vs TCRX Comparison

SYPR vs TCRX Comparison

Compare SYPR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SYPR

Sypris Solutions Inc.

HOLD

Current Price

$1.87

Market Cap

47.4M

Sector

Industrials

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.39

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYPR
TCRX
Founded
1997
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
49.4M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
SYPR
TCRX
Price
$1.87
$0.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
26.3K
763.4K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
$82,294,000.00
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$1.67
$0.35
52 Week High
$4.74
$2.57

Technical Indicators

Market Signals
Indicator
SYPR
TCRX
Relative Strength Index (RSI) 46.63 16.98
Support Level $1.73 N/A
Resistance Level $2.14 $0.82
Average True Range (ATR) 0.12 0.06
MACD 0.01 -0.04
Stochastic Oscillator 41.58 4.04

Price Performance

Historical Comparison
SYPR
TCRX

About SYPR Sypris Solutions Inc.

Sypris Solutions Inc provides products and engineering, design, and manufacturing services for a variety of critical infrastructure sectors, including energy, space, communications, defense, transport, chemical, and water. The company operates in two segments, Sypris Technologies and Sypris Electronics. Sypris Technologies segment includes the sale of forged, machined, welded and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications, whereas the Sypris Electronics segment includes revenue from circuit card and box build manufacturing, high reliability manufacturing and systems assembly and integration, for aerospace and defense, communications and space applications. The majority of revenue is derived from the Sypris Electronics segment.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: